Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ARDX - Ardelyx, Inc.
Market Cap 866.43M P/E - EPS this Y 13.30% Ern Qtrly Grth -
Income -65.14M Forward P/E -36.73 EPS next Y 73.10% 50D Avg Chg 13.00%
Sales 210M PEG -0.88 EPS past 5Y - 200D Avg Chg 27.00%
Dividend N/A Price/Book 7.15 EPS next 5Y 30.00% 52W High Chg -21.00%
Recommedations 1.50 Quick Ratio 3.58 Shares Outstanding 235.43M 52W Low Chg 453.00%
Insider Own 1.62% ROA -13.27% Shares Float 229.90M Beta 0.89
Inst Own 61.83% ROE -48.23% Shares Shorted/Prior 25.93M/25.98M Price 4.04
Gross Margin 66.27% Profit Margin -31.02% Avg. Volume 5,148,887 Target Price 11.65
Oper. Margin -18.62% Earnings Date Oct 29 Volume 10,175,200 Change 5.21%
Healthcare | Biotechnology | United States
About Ardelyx, Inc.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc. News
12/16/24 Ardelyx, Inc. (NASDAQ:ARDX): Is Breakeven Near?
11/20/24 Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
11/19/24 High Growth Tech Stocks To Explore In November 2024
11/18/24 US Penny Stocks To Monitor In November 2024
11/08/24 Ardelyx Responds to District Court Decision Granting Motion to Dismiss
11/05/24 Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
11/02/24 Ardelyx Third Quarter 2024 Earnings: US$0.003 loss per share (vs US$0.03 profit in 3Q 2023)
11/01/24 Q3 2024 Ardelyx Inc Earnings Call
11/01/24 Ardelyx Inc (ARDX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Amidst ...
10/31/24 Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics
10/31/24 Ardelyx (ARDX) Reports Break-Even Earnings for Q3
10/31/24 Ardelyx: Q3 Earnings Snapshot
10/31/24 Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
10/28/24 Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
10/28/24 Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
10/24/24 Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
10/24/24 Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline
10/22/24 Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
03:05 PM Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
10/18/24 Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Rosenbaum David P. Chief Development Of.. Chief Development Officer Jan 08 Sell 6.64 30,000 199,200 286,596 01/10/24
Renz Justin A Chief Financial Offi.. Chief Financial Officer Dec 26 Sell 6.36 225,000 1,431,000 182,426 12/28/23
Renz Justin A Chief Financial Offi.. Chief Financial Officer Dec 26 Option 0.99 75,000 74,250 407,426 12/28/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Dec 18 Sell 6.07 5,675 34,447 316,596 12/20/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Dec 14 Sell 5.55 7,000 38,850 322,271 12/15/23
GRAMMER ELIZABETH A See Remarks See Remarks Dec 11 Sell 5.0785 50,000 253,925 275,675 12/13/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Dec 08 Sell 5.2738 20,000 105,476 329,271 12/08/23
Williams Laura A Chief Medical Office.. Chief Medical Officer Nov 20 Sell 4.3622 2,581 11,259 266,191 11/22/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Nov 20 Sell 4.36 3,767 16,424 113,293 11/22/23
Rodriguez Susan Chief Commercial Off.. Chief Commercial Officer Nov 20 Sell 4.3622 4,714 20,563 346,973 11/22/23
Renz Justin A Chief Financial Offi.. Chief Financial Officer Nov 20 Sell 4.3622 2,873 12,533 332,426 11/22/23
RAAB MICHAEL President & CEO President & CEO Nov 20 Sell 4.3622 11,368 49,589 867,868 11/22/23
GRAMMER ELIZABETH A See Remarks See Remarks Nov 20 Sell 4.3622 2,384 10,399 325,675 11/22/23
Felsch Robert Ora See Remarks See Remarks Nov 20 Sell 4.3622 1,044 4,554 117,066 11/22/23
Blanks Robert See Remarks See Remarks Nov 20 Sell 4.3622 2,835 12,367 260,453 11/22/23
Williams Laura A Chief Medical Office.. Chief Medical Officer Nov 15 Sell 3.9999 25,000 99,998 266,839 11/17/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Oct 10 Sell 4 1,644 6,576 365,378 10/12/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Sep 08 Sell 4.55 2,897 13,181 367,022 09/12/23
Williams Laura A Chief Medical Office.. Chief Medical Officer Jun 27 Sell 3.3453 25,000 83,632 294,430 06/29/23
Blanks Robert See Remarks See Remarks Jun 23 Sell 3.63 33,333 120,999 266,134 06/27/23
Blanks Robert See Remarks See Remarks Jun 23 Option 3.42 33,333 113,999 299,467 06/27/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Mar 29 Sell 4.6293 3,000 13,888 113,096 03/31/23
Felsch Robert Ora See Remarks See Remarks Aug 31 Buy .6188 3,000 1,856 91,418 09/01/22
Rosenbaum David P. Chief Development Of.. Chief Development Officer Aug 31 Buy 0.62 3,000 1,860 92,369 09/01/22
Rosenbaum David P. Chief Development Of.. Chief Development Officer Aug 31 Sell 0.92 3,000 2,760 89,369 09/01/22
Renz Justin A Chief Financial Offi.. Chief Financial Officer Aug 31 Buy 0.6188 3,000 1,856 263,549 09/01/22
Williams Laura A Chief Medical Office.. Chief Medical Officer Aug 31 Buy 0.6188 3,000 1,856 245,441 09/01/22
RAAB MICHAEL President & CEO President & CEO Aug 31 Buy 0.6188 3,000 1,856 665,680 09/01/22
GRAMMER ELIZABETH A See Remarks See Remarks Aug 31 Buy 0.6188 3,000 1,856 256,110 09/01/22
Rodriguez Susan Chief Commercial Off.. Chief Commercial Officer Aug 22 Sell 0.98 3,420 3,352 286,173 08/24/22
Rosenbaum David P. Chief Development Of.. Chief Development Officer Aug 22 Sell 0.98 1,955 1,916 89,369 08/24/22
Blanks Robert See Remarks See Remarks Aug 22 Sell 0.98 1,458 1,429 317,669 08/24/22
RAAB MICHAEL President & CEO President & CEO Aug 22 Sell 0.98 6,146 6,023 662,680 08/24/22
GRAMMER ELIZABETH A See Remarks See Remarks Aug 22 Sell 0.98 1,236 1,211 253,110 08/24/22
Williams Laura A Chief Medical Office.. Chief Medical Officer Aug 22 Sell 0.98 1,276 1,250 242,441 08/24/22
Renz Justin A Chief Financial Offi.. Chief Financial Officer Aug 22 Sell 0.98 1,498 1,468 260,549 08/24/22
Renz Justin A Chief Financial Offi.. Chief Financial Officer Jun 06 Sell 0.64 73,312 46,920 262,047 06/08/22
Rodriguez Susan Chief Commercial Off.. Chief Commercial Officer Jun 06 Sell 0.64 43,920 28,109 289,593 06/08/22
Blanks Robert See Remarks See Remarks Jun 06 Sell 0.64 73,312 46,920 324,315 06/08/22
GRAMMER ELIZABETH A See Remarks See Remarks Jun 06 Sell 0.64 60,821 38,925 254,346 06/08/22
Rosenbaum David P. Chief Development Of.. Chief Development Officer Jun 06 Sell 0.64 61,640 39,450 89,866 06/08/22
RAAB MICHAEL President & CEO President & CEO Jun 06 Sell 0.64 103,624 66,319 668,826 06/08/22
Blanks Robert See Remarks See Remarks Feb 22 Sell 0.67 1,752 1,174 399,116 02/25/22
SANDELL SCOTT D 10% Owner 10% Owner Dec 09 Sell 1.32 2,881,570 3,803,672 2,258,850 12/27/21
BASKETT FOREST 10% Owner 10% Owner Dec 09 Sell 1.32 2,881,570 3,803,672 2,258,850 12/27/21
GRAMMER ELIZABETH A See Remarks See Remarks Dec 15 Option 2.32 42,000 97,440 113,527 12/15/20
GRAMMER ELIZABETH A See Remarks See Remarks Dec 15 Sell 7.3 42,000 306,600 72,527 12/15/20